Views: 0 Author: Kevin Fang Publish Time: 2026-09-15 Origin: Chensheng Medical
TL;DR —
Peristaltic pump tubing is one of the highest-risk silicone components in infusion and IV therapy devices because small shifts in wall thickness, durometer, post-cure state, or compression set can translate directly into flow-rate error, premature fatigue, leakage, or requalification cost. For OEM buyers, supplier approval should be based on ISO 13485 process control, USP <88> / ISO 10993 evidence, clean manufacturing discipline, and documented tolerance capability rather than generic “medical-grade” claims. Jinan Chensheng Medical Technology brings 40+ years of silicone manufacturing experience, 150+ skilled staff, an integrated in-house production system, and 80+ core technology patents covering material modification, extrusion, molding, and downstream quality control. For most custom pump-tubing programs, MOQ typically starts from 3,000–5,000 meters, samples are usually available in about 7 working days, and first production normally takes 12–18 working days after drawing approval.
USP Class VI silicone compound does not automatically equal a validated pump segment; flow stability depends on geometry, compression recovery, post-cure, and lot-to-lot consistency.
Food-grade or general industrial platinum-cured silicone is not a substitute for medical-use evidence under ISO 10993, USP <87>/<88>, and controlled manufacturing documentation.
For infusion applications, wall tolerance and concentricity often matter more than headline hardness numbers because pump accuracy can drift even when durometer stays nominally in spec.
Chensheng’s public positioning around in-house material modification, tooling, extrusion, molding, and QC under ISO 13485 reduces supplier-transfer risk compared with fragmented subcontract manufacturing.
Typical custom MOQ starts at 3,000–5,000 meters, while first-order production usually falls in the 12–18 working day range if drawings, tolerances, and validation scope are clearly defined.
The most expensive procurement mistake is approving a supplier on certificates alone without reviewing the exact formulation, post-cure window, traceability method, and pump-cycle performance data.
Peristaltic pump tubing in infusion sets and IV therapy devices operates under a different risk profile from general transfer tubing. In an infusion pump, the tubing is not a passive conduit. It is a functional metering element repeatedly compressed by rollers or fingers, and its elastic recovery directly affects delivered volume, startup delay, backflow behavior, and long-cycle durability.
That is why supplier qualification for this category should start with the intended device environment, not with a generic silicone brochure. Depending on the final product, the technical review often touches multiple standards and regulatory frameworks:
IEC 60601-2-24 for infusion pumps and controllers, where component variation can affect overall system accuracy
ISO 8536-4 for infusion equipment for single use, especially when tubing becomes part of disposable administration sets
ISO 10993-1, ISO 10993-5, ISO 10993-10, and ISO 10993-11 for biological evaluation logic and endpoint testing
USP <87> and USP <88> Class VI for biological reactivity evidence commonly used in medical silicone sourcing
ISO 14644-1 when the supplier claims controlled clean manufacturing
ISO 80369 if the broader device platform includes small-bore connector interfaces that interact with the tubing assembly
In practical sourcing, three questions should be answered before supplier approval:
Is the silicone formulation suitable for body-fluid-adjacent medical use?
Can the supplier hold dimensional and mechanical stability through long pump cycles?
Can the supplier maintain traceability and change control at production scale?
Many buying teams overfocus on the first question and underweight the second and third. That creates expensive surprises during verification builds. A pump segment can pass biocompatibility review but still fail device validation because wall thickness drifts from ±0.04 mm to ±0.10 mm, or because compression set changes after a shortened post-cure cycle.
Our technical blog center shows how these sourcing risks extend across broader medical silicone categories, including infusion, pharmaceutical tubing, and catheter programs.
Peristaltic pump assemblies used in infusion and IV therapy are rarely defined by one dimension alone. Buyers should break the silicone scope into separate component families and request data for each.
For the main pump segment, commonly reviewed parameters include:
Inner diameter (ID): 1.5 mm to 4.0 mm
Outer diameter (OD): 3.5 mm to 7.0 mm
Wall thickness: 0.8 mm to 1.8 mm
Hardness: 50 to 60 Shore A for the majority of pump-compatible designs
Wall tolerance: typically ±0.03 mm to ±0.08 mm, depending on size
Concentricity: often ≤ 0.10 mm for tighter-flow programs
Tensile strength: commonly ≥ 8.0 MPa
Elongation at break: often ≥ 350%
Compression set: preferably ≤ 25% at 175°C × 22 h for fatigue-sensitive sections
Recommended cycle validation: often 100,000 to 500,000 pump cycles, project dependent
In many infusion programs, a nominal durometer shift of only 3 Shore A can be less damaging than a wall-thickness drift of 0.06 mm. That is why serious OEM buyers should request both dimensional Cp/Cpk evidence and pump-simulation cycle data, not just a generic physical-property sheet.
If the infusion device includes silicone injection sites or resealable septa, the design logic changes:
Thickness: 2.0 mm to 4.5 mm
Hardness: 35 to 50 Shore A depending on puncture force and reseal target
Puncture force target: often reviewed with 20G to 22G needles or customer-specific access devices
Reseal performance: commonly validated after 10 to 30 puncture cycles
Tear resistance: should be checked if repeated access is expected
Flash control: critical at slit or molded gate areas
A septum that is too soft may reseal well but shed fragments during repeated puncture. A septum that is too hard may raise insertion force or compromise user handling.
Silicone diaphragms and seals for infusion systems typically require:
Membrane thickness: 0.30 mm to 1.00 mm
Hardness: 30 to 50 Shore A for opening sensitivity; 50 to 70 Shore A for static seals
Opening pressure: commonly 3 kPa to 15 kPa depending on valve architecture
Compression recovery: tightly linked to flow shutoff reliability
Assembly tolerance: especially critical at bonded or overmolded interfaces
For molded silicone components used next to pump tubing, material compatibility and cure-state consistency matter as much as absolute dimensions. A supplier that extrudes tubing and molds companion seals within one quality system usually shortens validation loops and reduces mismatch risk.
Our process selection guide for extrusion, injection molding, and compression molding shows how different manufacturing routes influence tolerances, surface finish, and downstream validation burden.
Buyers often ask whether the tubing is platinum-cured, but that is only a starting point. In pump applications, the more important questions are:
How stable is the compound under repeated occlusion?
How much hardness drift appears lot to lot?
How tightly is the post-cure window controlled?
What release checks are used before shipment?
Is the formulation locked against unauthorized changes?
For infusion pump segments, the preferred platform is often a medical-grade silicone formulation optimized for:
low compression set
stable rebound after repeated roller compression
low extractable residue
good clarity for visual line inspection
balanced tear strength and elongation
Typical target ranges buyers may request include:
Hardness: 52 to 58 Shore A for pump segments
Tear strength: ≥ 25 kN/m
Specific gravity: approximately 1.12 to 1.20 depending on formulation family
Volatile management: documented through internal post-cure and release control
Surface quality: no tackiness, no visible gel particles, no die lines affecting pump contact
Post-cure is one of the most underrated variables in medical silicone sourcing. A tubing lot may pass ID/OD inspection but still underperform in pump life if post-cure is shortened from 6 hours to 3 hours at 190°C, or if the thermal window shifts outside the validated range. Common consequences include:
higher compression set
odor or volatile inconsistency
tacky surface feel
changed recovery speed under cyclic load
greater batch-to-batch variation after ETO conditioning
Based on your public website, Chensheng’s key differentiator is not a vague “premium silicone” claim; it is vertical process control. The company presents itself as handling raw-material modification, tooling and mold development, extrusion, molding, and quality assurance in-house under an ISO 13485-certified quality system, supported by 80+ core technology patents and long-term cooperation with hospitals and medical research institutions.
That matters because many supplier failures come from fragmented subcontracting. When compounding, extrusion, post-cure, and inspection are spread across separate parties, the OEM inherits additional risk in batch coding, parameter transfer, and undocumented process changes. For the live page, this section will become even stronger if you insert the verified patent numbers related to silicone formulation, extrusion die design, or catheter/tubing structure.
Our medical silicone manufacturing overview shows the full in-house scope that supports tubing, catheters, and molded medical components, while our USP Class VI vs. ISO 10993 buyer guide helps buyers evaluate the documentation behind those process claims.
A strong compliance package should be reviewed item by item, not treated as a single checkbox.
This is the supplier’s quality-management backbone. Buyers should confirm:
certificate validity date
issuing body
exact scope, including silicone extrusion, molding, or related medical-component manufacturing
change-control procedure
complaint handling and CAPA readiness
traceability from raw material lot to finished goods lot
For medical silicone compounds, these reports often provide foundational evidence of biological reactivity performance. Buyers should check:
sample identity or formulation code
whether the report applies to the exact compound or only a base polymer family
testing laboratory, such as SGS, TÜV, Intertek, or another recognized institution
issue date, ideally within the last 24–36 months unless supported by formal change control
For infusion components, the most frequently reviewed endpoints include:
ISO 10993-5 cytotoxicity
ISO 10993-10 irritation and sensitization
ISO 10993-11 acute systemic toxicity
ISO 10993-18 chemical characterization where extractables or contact-risk logic requires it
The key point is scope. A test on raw silicone stock may not fully represent a finished pump segment after extrusion, post-cure, and packaging.
If the supplier claims clean manufacturing, ask for:
cleanroom class
particle-count records
pressure differential logs
temperature and humidity logs
gowning and cleaning procedures
For ISO Class 7, one standard reference point is a maximum of 352,000 particles/m³ at 0.5 µm under the classification framework. In routine production, buyers also often expect pressure differentials around 10–15 Pa, temperature around 20–24°C, and relative humidity around 30–60%, depending on the process layout.
Our remote factory audit guide for Chinese medical silicone manufacturers shows how to verify these documents and controls during supplier qualification without waiting for an on-site visit.
Professional medical buyers prefer predictable timelines, not vague “fast delivery” claims. For custom pump tubing programs, the process should be broken into traceable stages.
The supplier reviews:
intended device type
flow-rate sensitivity
target market
sterilization route
annual forecast
drawings, 2D tolerances, or reference sample
Engineering should propose:
hardness range
achievable ID/OD tolerance
wall-thickness window
recommended post-cure profile
packaging and labeling options
validation risks to be addressed early
For standard single-lumen pump tubing, die preparation is relatively fast. For special tolerance bands, radiopaque stripes, color coding, or paired sealing components, lead time can extend.
A robust sample package should include:
dimensional inspection data
visual inspection results
basic physical-property data
lot code reference
optional trial report if pump simulation is performed internally
This stage commonly addresses:
fit in pump head
flow drift
compression recovery
transparency
connector fit or bonding behavior
For regulated projects, buyers often request:
first article dimensions
appearance standard
packaging verification
traceability review
approved sample retention
This range is realistic for many custom tubing projects once drawings and approval criteria are fixed. Delays usually come from unclear tolerances, missing validation expectations, or late documentation changes, not from extrusion alone.
Our process selection article and technical resource center help buyers map product complexity to the right manufacturing route before RFQ release.
The fastest way to demonstrate technical credibility is to show where projects actually fail.
A supplier ships tubing at 56 Shore A, exactly matching the drawing, yet the finished infusion set shows unstable flow in verification. Root cause analysis later finds wall thickness drifting between 1.02 mm and 1.15 mm when the nominal wall was 1.08 mm ± 0.04 mm. The material was acceptable; the geometry was not. Buyers who approve only by hardness and biocompatibility reports miss this risk.
The sample lot performs well, but production lots begin cracking or showing slow recovery after storage and ETO exposure. Investigation reveals that the supplier shortened post-cure time to recover throughput. Compression set remained unmonitored, and no customer-facing formulation lock existed. In other words, the qualification sample and the production state were no longer equivalent.
This happens more often than buyers expect in lower-discipline supply chains. The tubing still looks acceptable, but odor, transparency, or particulate performance shifts. Because the purchase specification did not define change-notification triggers, the OEM discovers the issue only during complaint review or revalidation.
The corrective action pattern is consistent:
lock the formulation
lock the critical process window
define customer-notification triggers
qualify the finished article, not only the generic compound
Our remote factory audit guide shows how to ask for this evidence during supplier evaluation rather than after a failure.
The following anonymized case reflects a typical regulated sourcing project for pump-segment tubing used in a home-infusion device sold through OEM and private-label channels in Germany and the Benelux market.
Market: Germany, Netherlands, Belgium
Channel: home-care OEM supply and private-label distribution
Product: transparent peristaltic pump segment tubing plus molded silicone seal
Compliance basis: ISO 13485 supplier approval, USP <88> Class VI compound evidence, ISO 10993-5/-10 review, clean manufacturing documentation
Initial pain point: previous supplier had acceptable pricing but unstable wall tolerance, causing flow-calibration rework at incoming inspection
Week 1–2: NDA signed, drawing reviewed, pump-head geometry confirmed, target flow profile discussed.
Week 3: DFM feedback recommended tightening wall control and adjusting nominal hardness from 54 Shore A to 57 Shore A to improve recovery under repeated occlusion.
Week 4: die preparation and compound confirmation completed.
Week 5: first samples shipped with full dimensional data and lot coding.
Week 6: customer tested cycle life and requested narrower OD tolerance.
Week 7: revised samples approved.
Week 8: remote quality audit completed and documentation package aligned to approved vendor list format.
Week 9–10: pilot lot produced and first article released.
Week 11–12: first production order shipped.
Previous unit cost: USD 0.129 equivalent per pump segment
New unit cost: USD 0.097 equivalent
Cost reduction: 24.8%
Previous first-order lead time: 26 working days
New first-order lead time: 15 working days
Incoming rejection rate: reduced from 7.4% to 1.9% over the initial three shipments
Pump calibration adjustment time: reduced by approximately 31% at the customer’s assembly site
“The most useful improvement was not price alone. It was the consistency of the sample-to-production transition and the clarity of the dimensional data package.”
Our medical silicone manufacturing page and technical article library provide supporting context for buyers comparing infusion-component suppliers across compliance, engineering, and lead-time criteria.
The most productive RFQs are structured with realistic commercial ranges from the beginning.
MOQ: 5,000 to 10,000 meters
Sample lead time: 5 to 7 working days
First production: 12 to 15 working days
Reference price: approximately USD 0.35 to USD 2.20 per meter, depending on size, clarity, and packaging
MOQ: 3,000 to 5,000 meters
Sample lead time: around 7 working days
First production: 12 to 18 working days
Reference price: approximately USD 0.80 to USD 3.80 per meter, depending on tolerance, hardness window, and documentation depth
MOQ: 5,000 to 20,000 sets or pieces, depending on structure
Sample lead time: 7 to 12 working days
First production: 15 to 25 working days
Reference price: approximately USD 0.12 to USD 1.80 per molded part, excluding specialized tooling or validation support
If the program includes customer-specific CoA format, extended FAI, retained samples, or supplier-quality agreement review, buyers should expect documentation work to affect both cost and lead time. In regulated medical sourcing, documentation engineering is part of the product.
Our pharmaceutical silicone tubing compliance guide is also useful for procurement teams who need stronger extractables and traceability discipline in adjacent fluid-path applications.
Before placing a trial order or approving a supplier for pump tubing, confirm the following:
Ask whether the biocompatibility reports apply to the exact finished compound and cure system, not just a generic silicone family.
Request the supplier’s achievable wall tolerance and concentricity capability for your exact tubing size.
Ask for the post-cure temperature and time window used in routine production.
Confirm whether the supplier supports a formulation lock and change-notification agreement.
Request cycle-life or compression-recovery data if the tubing is used in a metering pump segment.
Verify that the ISO 13485 certificate scope covers the actual extrusion and molding processes offered.
Ask for a sample of the lot-traceability format, from raw silicone lot to finished shipping label.
Confirm whether the tubing is made in an ISO-controlled clean environment and request recent monitoring records.
Ask which tests are performed in-house and which are outsourced to SGS, TÜV, Intertek, or equivalent labs.
Confirm realistic MOQ, sample lead time, pilot timing, and first-order production timing before approving the drawing.
This is incomplete because “medical grade” does not confirm wall control, fatigue behavior, or change control.
Correct approach: review formulation identity, biocompatibility scope, pump-cycle performance, and dimensional capability together.
This is misleading because tubing can meet 55 Shore A and still fail pump accuracy if wall thickness drifts.
Correct approach: prioritize ID/OD tolerance, wall variation, concentricity, and compression recovery alongside hardness.
This is risky because production performance can change when cure and post-cure windows shift.
Correct approach: define the validated thermal window and include it in the supplier quality agreement.
A USP or ISO 10993 report without compound code or process relevance may have limited audit value.
Correct approach: request exact formulation references, issue dates, and test-laboratory details.
This often hides the bigger cost drivers: incoming rejection, calibration time, validation rework, and supply delays.
Correct approach: compare total landed cost, process stability, and documentation readiness.
By then, the supplier may already have altered raw materials, catalysts, or process settings.
Correct approach: define change-control triggers before the first approved sample is released.
Peristaltic pump silicone tubing should be sourced as a precision functional component, not as a commodity tube. The right supplier must combine biocompatibility evidence, tight dimensional control, stable post-cure management, clean manufacturing, and disciplined change control. For infusion and IV therapy programs, wall tolerance, compression recovery, and traceability usually drive long-term cost more than the nominal material claim alone.
Share your drawing, target market, pump type, flow-rate sensitivity, sterilization method, and annual forecast with our team. We can typically confirm the basic compliance path within 24 hours and provide a DFM feasibility assessment within 48 hours for most pump-tubing and silicone-component programs.
Kevin Fang | 21 years in silicone OEM/ODM manufacturing
Jinan Chensheng Medical Technology Co., Ltd. | 40+ years of medical silicone manufacturing history | 150+ skilled employees | 80+ core technology patents | ISO 13485-certified quality management system | experience supporting Class III hospitals, pharmaceutical manufacturers, and medical device OEMs
Contact: https://www.jngxj.cn/ | WhatsApp: +86-18560016197
For many infusion-pump applications, the working range is typically 50 to 60 Shore A, with 52 to 58 Shore A often used as a starting engineering window for pump segments. However, hardness alone is not enough. A tubing lot at 56 Shore A can still produce unstable flow if wall thickness varies outside the validated band or if post-cure changes compression recovery. Buyers should therefore request not only a durometer target, but also wall tolerance, concentricity, compression-set data, and cycle-life evidence. In regulated programs, the best qualification logic links hardness to actual pump performance, not just to the raw material data sheet.
No. USP <88> Class VI is useful evidence of biological reactivity performance, but it does not automatically validate the tubing as a finished metering component in an infusion system. Device approval decisions typically need broader evidence, including ISO 10993 endpoint review, process control under ISO 13485, and engineering suitability such as dimensional capability, occlusion recovery, and pump-cycle stability. If the tubing is extruded, post-cured, cut, cleaned, and packaged differently from the material used in the lab report, buyers should verify whether the original evidence still applies to the final article.
The most critical dimensions are usually ID, OD, wall thickness, and concentricity, but in practice wall thickness variation often has the strongest effect on flow accuracy. Typical pump-segment designs may fall in the range of 1.5–4.0 mm ID, 3.5–7.0 mm OD, and 0.8–1.8 mm wall thickness, depending on the pump architecture. Buyers should ask the supplier for actual process capability by size family, such as whether the wall can be held within ±0.03 mm, ±0.05 mm, or ±0.08 mm. A specification sheet without demonstrated capability can lead to pump recalibration issues, incoming rejection, or unstable validation results.
For most custom medical programs, MOQ typically starts around 3,000 to 5,000 meters for dedicated pump-segment tubing, while standard single-lumen tubing is often closer to 5,000 to 10,000 meters. The exact MOQ depends on diameter, wall tolerance, hardness range, whether color coding is required, and whether the project includes companion molded silicone parts such as seals or septa. Very small diameters or unusually tight tolerances may push MOQ higher because line setup, die stabilization, and inspection cost increase. Buyers should ask for MOQ together with sample lead time and pilot-lot timing, not as an isolated commercial number.
For a straightforward custom pump-tubing project, a common timeline is 1–2 working days for RFQ and application review, 2–4 days for DFM and material recommendation, 3–7 days for die preparation, around 7 days for sample production, and then 12–18 working days for first mass production after sample approval. More complex projects may take longer if they involve molded seals, customer-specific inspection reports, validation support, or formal supplier-quality agreement review. In medical sourcing, delays usually come from unclear acceptance criteria rather than from extrusion alone.
At minimum, request the supplier’s ISO 13485 certificate, the exact USP <87>/<88> and ISO 10993 reports relevant to the compound or finished part, a sample of the lot-traceability format, and evidence of clean manufacturing if claimed, such as ISO 14644-1 records. For pump tubing specifically, buyers should also request dimensional capability data, the target post-cure window, and any available compression-recovery or pump-cycle test information. If the supplier cannot connect the test report to the actual production formulation and lot-release process, the certificate package may be weaker than it appears.
Post-cure directly affects volatile reduction, compression set, surface feel, odor, and elastic recovery. For a pump segment that undergoes repeated occlusion, those changes can influence cycle life and flow stability even when ID, OD, and hardness remain nominally in spec. For example, changing post-cure from 190°C × 6 hours to 190°C × 3 hours can alter the functional state of the tubing enough to trigger validation drift, especially after storage or ETO exposure. Buyers should therefore ask suppliers to define the normal post-cure window and to treat any change in that window as a controlled process change, not as an internal housekeeping adjustment.
The best approach is to combine technical approval with a written formulation lock and change-notification mechanism. That means defining which variables cannot be changed without prior customer approval: raw polymer source, catalyst system, pigments, post-cure profile, die configuration, packaging format, or cleanroom process. Buyers should also retain an approved sample, align the CoA format to incoming inspection, and require traceability from raw silicone lot to finished shipment label. In long-life medical programs, the supplier with the lowest quoted price is not always the lowest-cost supplier once validation rework, complaint handling, and audit burden are included.
